Table 3.
Association between DNA methylation-based IFN score level and clinical manifestations of primary Sjögren’s syndrome (pSS).
| Phenotype‡ | Discovery and replication cohort together, n=148 | ||
|---|---|---|---|
| DNAm IFN score, mean (±s.d.), n | P-value | ||
| Positive phenotype | Negative phenotype | ||
| Leucopenia (< 4.0x109/L) | 7.0 (±4.6), n=56 | 5.0 (±4.2), n=90 | 0.010 |
| P-IgG > 15 g/L | 8.1 (±3.7), n=65 | 3.6 (±4.0), n=62 | 2.0x10-8 |
| C3 below normal limit | 5.1 (±5.9), n=13 | 6.3 (±4.1), n=106 | 0.41 |
| C4 below normal limit | 10.3 (±1.6), n=12 | 5.5 (±4.6), n=51 | 1.5x10-3 |
| GC formation in minor salivary glands | 5.9 (±3.8), n=16 | 5.2 (±4.5), n=55 | 0.60 |
| Raynaud’s phenomenon | 5.1 (±4.3), n=53 | 6.1 (±4.6), n=94 | 0.17 |
| Arthritis | 6.3 (±4.7), n=21 | 5.6 (±4.4), n=126 | 0.61 |
| Purpura | 6.6 (±3.7), n=10 | 5.7 (±4.5), n=137 | 0.63 |
| Lymphadenopathy | 5.7 (±4.2), n=28 | 5.7 (±4.5), n=119 | 0.95 |
| Hypothyroidism | 5.9 (±4.3), n=35 | 5.7 (±4.5), n=112 | 0.82 |
| Lymphoma, all | 6.3 (±5.5), n=15 | 5.7 (±4.3), n=133 | 0.62 |
| Lymphoma onset at or after sampling, all (range 0-12 years) | 7.7 (±5.3), n=9 | 5.7 (±4.3), n=133 | 0.20 |
| Lymphoma onset at or after sampling, <70 years (range 0-12 years) | 9.5 (±4.9), n=7 | 5.7 (±4.3), n=133 | 0.025 |
| Lymphoma prior to sampling (range -5 to -19 years) | 4.2 (±5.3), n=6 | 5.7 (±4.3), n=133 | 0.45 |
‡Clinical manifestations presented ever.
DNAm-based IFN score levels are reported as mean IFN score ±s.d. in patients with pSS stratified on their status for each of the disease manifestations included in the analysis. Continuous variables between groups were tested using Mann-Whitney U.
C3, complement component 3; C4, complement component 4; GC, germinal center; P-IgG, plasma immunoglobulin G.
Significant p-values in bold.